EGFR S492R Mutation Detection for Cetuximab Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies using monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) for metastatic colorectal cancer and head and neck cancer are hindered by primary and secondary resistance mechanisms, with existing biomarkers providing incomplete predictive value for treatment response.
Innovation Solution
Identification of a specific mutation in the EGFR protein, S492R, which interferes with the binding of cetuximab but not panitumumab, allowing for the development of peptide sequences, oligonucleotides, and primers to detect this mutation and predict treatment response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If monoclonal antibodies (cetuximab) are used to treat metastatic colorectal cancer, then significant survival benefit is achieved, but primary and secondary resistance mechanisms limit treatment effectiveness
Solution Approach 1:
The patent performs preliminary detection of the S492R mutation in the EGFR gene before initiating cetuximab treatment. By identifying patients with this specific mutation upfront, the system prevents ineffective treatment administration, thereby avoiding the development of resistance and optimizing initial treatment selection.
Solution Approach 2:
The patent establishes a feedback mechanism where treatment response is monitored and correlated with the presence of the S492R mutation. This feedback loop allows clinicians to adjust treatment strategies based on genetic test results, switching from cetuximab to panitumumab when the mutation is detected, thereby overcoming resistance issues.
2Measurement precision
If existing biomarkers are used to predict treatment response, then some predictive value is obtained, but the predictive accuracy is insufficient
Solution Approach 1:
The patent changes the predictive parameter from general EGFR expression levels or common biomarkers to a specific nucleotide substitution (S492R mutation) in the EGFR gene. This parameter change dramatically improves predictive accuracy for cetuximab resistance, enabling precise identification of patients who will not respond to cetuximab therapy.
Solution Approach 2:
The patent replaces conventional biomarker detection methods with targeted molecular genetic testing for the S492R mutation. This substitution provides more accurate and reliable predictive information, eliminating the incomplete prediction associated with traditional biomarkers.
3Productivity
If cetuximab therapy is administered without mutation testing, then treatment can be started immediately, but ineffective treatment is administered to patients with S492R mutation
Solution Approach 1:
The patent implements preliminary genetic testing for the S492R mutation before initiating cetuximab therapy. This preliminary action ensures that only appropriate patients receive cetuximab, preventing wasteful administration to resistant patients while maintaining efficient treatment initiation for responsive patients.
Solution Approach 2:
The patent extracts and tests for the specific S492R mutation from the complex EGFR gene sequence. By isolating this critical genetic marker, the system enables rapid decision-making about treatment appropriateness without requiring comprehensive genomic analysis, thus maintaining treatment initiation efficiency.
Data Source
AI summary
The invention relates to a new identified mutation in the epidermal growth factor receptor gene, leading to an amino acidic change which highly correlates with the resistance to a therapy regimen comprising cetuximab and the sensitivity to a therapy regimen comprising panitumumab. The invention includes peptide sequences, primers and probes to detect such a mutation, as well as kits for predicting the response of a subject to a therapy regime comprising cetuximab and/or panitumumab. In particular, the invention is useful in the therapy regimen applicable to metastasic colorectal cancer and to head and neck cancer.